Silence Therapeutics

In News

Spotlight On Silence Therapeutics And 2 Other Promising Penny Stocks - Yahoo Finance

Yahoo Finance - May 16, 2025

Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - Business Wire

Business Wire - May 08, 2025

Silence slows phase 3 plans for cardio drug, as Hansoh opts out of $1.3B biobucks collab - Fierce Biotech

Fierce Biotech - Feb 27, 2025

Goldman Sachs Initiates Coverage of Silence Therapeutics plc - Depositary Receipt () (SLN) with Sell Recommendation - Nasdaq

Nasdaq - Feb 11, 2025

Investors tell Silence Therapeutics to shush - STAT

STAT - Nov 20, 2024

Can Silence Therapeutics Deliver on its Pipeline Promise After Strong Financial Results? - Stock Titan

Stock Titan - Feb 27, 2025

These Analysts Think Silence Therapeutics plc's (NASDAQ:SLN) Sales Are Under Threat - simplywall.st

simplywall.st - Mar 06, 2025

Buy Rating on Silence Therapeutics: Promising Developments in Divesiran and Zerlasiran Programs - TipRanks

TipRanks - Jun 13, 2025

Silence Therapeutics Releases Late-Breaking Phase 2 Zerlasiran Data - Diagnostic and Interventional Cardiology

Diagnostic and Interventional Cardiology - Nov 18, 2024

Silence Therapeutics’s SWOT analysis: gene therapy stock faces pivotal year - Investing.com

Investing.com - May 24, 2025

Silence Therapeutics: Simply No Match For Its Orally Dosed Rival (Downgrade) (NASDAQ:SLN) - Seeking Alpha

Seeking Alpha - Jan 03, 2025

Silence delays zerlasiran Phase III launch as it scouts for partners - FirstWord Pharma

FirstWord Pharma - Feb 27, 2025

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.